Chew Minmin, S.
Bacotti, A.
Chen, Y.
Anders, C.
Sambade, M.
Deal, A. M.
Trembath, D.
McKee, M. J.
Brogi, E.
Seidman, A. D. http://orcid.org/0000-0002-5064-3966
Article History
Received: 4 August 2022
Accepted: 2 January 2023
First Online: 17 March 2023
Declarations
:
: CKA discloses Research funding: PUMA, Lilly, Merck, Seattle Genetics, Nektar, Tesaro, G1-Therapeutics, ZION, Novartis, Pfizer, Elucida; Compensated consultant role: Genentech, Eisai, IPSEN, Seattle Genetics, Astra Zeneca, Novartis, Immunomedics, Elucida, Athenex; Royalties: UpToDate, Jones and Bartlett. The other authors have no relevant financial or non-financial interests to disclose.
: The study was conducted according to the guidelines of the Declaration of Helsinki. Ethical review and approval were waived for this study, as this was a retrospective observational study of data obtained for clinical purposes. This study was registered under Memorial Sloan Kettering IRB waiver #WA0125-06.
: Patient consent was waived due to retrospective data being collected anonymously for a quality improvement process that aimed to improve patient care and outcomes through systematic review of care against explicit criteria and standards.